Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Stifel cut Carnival Corp (NYSE:CCL) price target from $40 to $35. Stifel analyst Steven Wieczynski maintained a Buy rating. Carnival shares closed at $26.21 on Tuesday. See how other analysts view this stock.
- Citizens cut the price target for Sharplink Inc (NASDAQ:SBET) from $50 to $40. Citizens analyst Devin Ryan maintained a Market Outperform rating. Sharplink shares closed at $7.39 on Tuesday. See how other analysts view this stock.
- Baird slashed Kohls Corp (NYSE:KSS) price target from $24 to $20. Baird analyst Mark Altschwager maintained a Neutral rating. Kohls shares closed at $14.58 on Tuesday. See how other analysts view this stock.
- Guggenheim cut the price target for Accenture Plc (NYSE:ACN) from $305 to $275. Guggenheim analyst Jonathan Lee maintained a Buy rating. Accenture shares closed at $201.63 on Tuesday. See how other analysts view this stock.
- Clear Street raised the price target for MoonLake Immunotherapeutics (NASDAQ:MLTX) from $45 to $70. Clear Street analyst Kaveri Pohlman maintained a Buy rating. MoonLake Immunotherapeutics shares closed at $18.34 on Tuesday. See how other analysts view this stock.
- B of A Securities cut Biomarin Pharmaceutical Inc (NASDAQ:BMRN) price target from $97 to $85. B of A Securities analyst Geoff Meacham maintained a Buy rating. Biomarin Pharmaceutical shares closed at $60.89 on Tuesday. See how other analysts view this stock.
- HC Wainwright & Co. increased LifeMD Inc (NASDAQ:LFMD) price target from $9 to $10. HC Wainwright & Co. analyst Yi Chen maintained a Buy rating. LifeMD shares closed at $3.91 on Tuesday. See how other analysts view this stock.
- Ascendiant Capital cut Outlook Therapeutics Inc (NASDAQ:OTLK) price target from $10 to $6. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Outlook Therapeutics shares closed at $0.44 on Tuesday. See how other analysts view this stock.
- Piper Sandler cut the price target for Oracle Corp (NYSE:ORCL) from $240 to $210. Piper Sandler analyst Billy Fitzsimmons maintained an Overweight rating. Oracle shares closed at $149.40 on Tuesday. See how other analysts view this stock.
- Mizuho raised Uniqure NV (NASDAQ:QURE) price target from $12 to $35. Mizuho analyst Uy Ear upgraded the stock from Neutral to Outperform. Uniqure shares closed at $18.26 on Tuesday. See how other analysts view this stock.
Considering buying QURE stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments